Research programme: potassium channel antagonists - Amgen

Drug Profile

Research programme: potassium channel antagonists - Amgen

Latest Information Update: 10 Sep 2008

Price : $50

At a glance

  • Originator Amgen
  • Class Antibodies; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Aug 2004 Tularik has been acquired and merged into Amgen
  • 15 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)
  • 13 Mar 2003 No development reported - Preclinical for Breast cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top